PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
Eli Lilly's recent quarter was extremely strong, with small beats on Mounjaro and Zepbound in the U.S. In the third quarter, Thermo's organic revenue growth improved to 3%. The path forward for uniQure is currently unclear and could range from additional analyses to a long randomized placebo controlled trial. Getty Images The following segment was excerpted from the PGIM Jennison Health Sciences Fund Q4 2025 Commentary. The S&P Composite 1500 Health Care Index advanced 11.2% in the fourth quarter, outperforming the S&P 500, which gained 2.7%. Pharmaceuticals and life sciences tools & services outperformed This article was written by Quick Insights LLY's lack of major patent expirations, strong commercial execution, and continued Mounjaro/Zepbound outperformance—especially ex-U.S.—support sustained growth and raised guidance. ARQT guided to $455-470M in 2026, above the $439M consensus, with Zoryve's expanding indications and market share as primary growth catalysts.
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) was downgraded by HSBC Holdings plc from "hold" to "reduce". They now have a $850.00 price target on the stock.MarketBeat
- Ireland courts U.S. companies as taoiseach brings deals to Trump on St. Patrick's Day [Fortune]Fortune
- Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans [Yahoo! Finance]Yahoo! Finance
- Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Pediatric EBGLYSS Data Strengthens Broader Immunology Growth Story [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/6/26 - Form PRE
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website